Research & Regulatory News

CagriSema After REDEFINE 4

UKPWritten and published by UK Peptides2 min readUpdated 5 cited sources

The short answer

CagriSema was filed with the FDA in December 2025 on the REDEFINE programme. Novo Nordisk expected a decision in the fourth quarter of 2026 (report of 4 November 2026); none had been announced by 21 November 2026. REDEFINE 4's failure to demonstrate non-inferiority against tirzepatide does not by itself block approval, because approval is assessed against placebo-controlled evidence.

Key facts

Filed with FDA
December 2025
Supporting trials
REDEFINE 1 and REDEFINE 2
Expected decision
Q4 2026 (Novo Nordisk, 4 November 2026)
PDUFA date
Not publicly confirmed (21 November 2026)
REDEFINE 4
NCT06131437: non-inferiority not met
REDEFINE 1
22.7% / 20.4% at 68 weeks
UK status
No MHRA authorisation

What an approval is actually assessed on

Whether a medicine is safe and effective for its proposed indication, judged largely against placebo-controlled evidence. That is what REDEFINE 1 and REDEFINE 2 provide. A comparative trial against a competitor answers a different question (how it ranks), which matters commercially and to prescribers rather than to the basic approvability decision.

So what did REDEFINE 4 change

The commercial picture rather than the regulatory one. A compound entering a market where the established option performed better in a direct comparison faces a harder argument with prescribers and payers, regardless of what its label says. That is a real consequence and it is not the same as a regulatory obstacle.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Where the filing stands

Submitted to the FDA in December 2025 on the REDEFINE Phase 3 programme. On 4 November 2026 Novo Nordisk said it expected a decision in the fourth quarter of 2026. As of 21 November 2026 no decision and no PDUFA date had been made public. If approved it would be the first once-weekly GLP-1 and amylin analogue combination for weight management.

Why the amylin approach is not settled by this

REDEFINE 4 compared a specific two-molecule combination at a specific dose pair against tirzepatide 15 mg. It did not test amylin as a mechanism. Single-molecule GLP-1 and amylin agonists such as amycretin are in Phase 3 development, and their results will speak to the target in a way this trial could not.

The UK position

CagriSema holds no MHRA authorisation and is not available in the UK. A US approval would not change that. The MHRA assesses separately, and UK availability additionally depends on NICE appraisal for NHS funding, which is a further and distinct process.

What none of this concerns

Research material. CagriSema is an investigational medicine under regulatory review, composed of two licensed-medicine components administered in registered trials. Nothing supplied here relates to it or is an alternative to any weight-management medicine.

Frequently asked questions

Does a failed head-to-head block approval?

No. Approval is assessed largely against placebo-controlled evidence, which REDEFINE 1 and 2 provide. A comparative trial answers a commercial question.

When is the FDA decision expected?

Novo Nordisk said on 4 November 2026 that it expected one in the fourth quarter of 2026. None had been announced by 21 November 2026, and no PDUFA date has been made public.

Is CagriSema available in the UK?

No. It holds no MHRA authorisation, and a US approval would not change that.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Research & Regulatory News articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.